Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay Gogia

Showing results (171-180 of 180) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 180 results.
Leukemia|July 29, 2024
Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphomaUdita Jindal, Mukesh Mamgain, Uttam Kumar Nath, et al.
The Indian Journal of Medical Research|November 9, 2022
Characteristics & outcomes of cancer patients with COVID-19: A multicentre retrospective study from IndiaAkash Kumar, Saphalta Baghmar, Prashant Mehta, et al.
Scientific Reports|August 12, 2024
Somatic mutational landscape across Indian breast cancer cases by whole exome sequencingRahul Kumar, Supriya Awasthi, Dibyabhaba Pradhan, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|August 22, 2018
Management of Lymphomas: Consensus Document 2018 by an Indian Expert GroupReena Nair, Abhishek Kakroo, Ajay Bapna, et al.
Trials|February 26, 2025
A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)Adhip Arora, V Seenu, Rajinder Parshad, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2025
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in IndiaSmeeta Gajendra, Tanima Dwivedi, Karthik Bommannan, et al.
Clinical Breast Cancer|July 28, 2024
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast CancerRushabh Kothari, Maulik Doshi, P K Chaithanya, et al.
Leukemia|January 12, 2023
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONYLarry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, et al.
Leukemia|December 24, 2022
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONYLarry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, et al.
Eclinicalmedicine|November 30, 2023
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYThomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, et al.
Pageof 18

Showing results (171-180 of 180) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Leukemia|July 29, 2024
Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphomaUdita Jindal, Mukesh Mamgain, Uttam Kumar Nath, et al.
The Indian Journal of Medical Research|November 9, 2022
Characteristics & outcomes of cancer patients with COVID-19: A multicentre retrospective study from IndiaAkash Kumar, Saphalta Baghmar, Prashant Mehta, et al.
Scientific Reports|August 12, 2024
Somatic mutational landscape across Indian breast cancer cases by whole exome sequencingRahul Kumar, Supriya Awasthi, Dibyabhaba Pradhan, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|August 22, 2018
Management of Lymphomas: Consensus Document 2018 by an Indian Expert GroupReena Nair, Abhishek Kakroo, Ajay Bapna, et al.
Trials|February 26, 2025
A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)Adhip Arora, V Seenu, Rajinder Parshad, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 13, 2025
Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in IndiaSmeeta Gajendra, Tanima Dwivedi, Karthik Bommannan, et al.
Clinical Breast Cancer|July 28, 2024
A Randomized, Double-Blind, Phase III Study in India for Comparing Efficacy, Safety, and PK of ZRC-3277 (Pertuzumab Biosimilar) With Perjeta® in Patients With HER2-Positive Metastatic Breast CancerRushabh Kothari, Maulik Doshi, P K Chaithanya, et al.
Leukemia|January 12, 2023
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONYLarry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, et al.
Leukemia|December 24, 2022
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONYLarry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, et al.
Eclinicalmedicine|November 30, 2023
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONYThomas Chatzikonstantinou, Lydia Scarfò, Georgios Karakatsoulis, et al.
Pageof 18